SIREN : 451879621
HANDI-PHARM GROUPE is a French company founded 22 years ago, specialized in the sector Activités des sociétés holding. Based in CHANTONNAY (85110), this company of category ETI shows in 2024 a revenue of 4.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 746 415 € | 5 481 425 € | 4 676 641 € | 3 564 914 € | 3 290 504 € | 3 124 579 € | 2 979 605 € | 2 381 995 € | 1 885 619 € |
| Net income | 342 363 € | 452 429 € | 921 525 € | 1 284 686 € | 161 422 € | 292 488 € | 735 250 € | 443 974 € | 620 164 € |
| EBITDA | 417 135 € | 492 847 € | 289 083 € | 183 793 € | 113 892 € | 153 121 € | 18 369 € | 80 485 € | 89 891 € |
| Net margin | 7.2% | 8.3% | 19.7% | 36.0% | 4.9% | 9.4% | 24.7% | 18.6% | 32.9% |
In 2024, HANDI-PHARM GROUPE achieves revenue of 4.7 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +12.2%. Significant drop of -13% vs 2023. After deducting consumption (743 k€), gross margin stands at 4.0 M€, i.e. a rate of 84%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 417 k€, representing 8.8% of revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 342 k€, i.e. 7.2% of revenue. This profit can be retained or distributed to shareholders.
4 746 415 €
4 003 445 €
417 135 €
226 364 €
342 363 €
8.8%
The debt ratio (= Financial debt / Equity x 100) stands at 115%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 44%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 11.9 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 18.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
114.877%
43.658%
18.526%
11.877
22.0%
In 2024, the debt ratio of HANDI-PHARM GROUPE (114.88) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of HANDI-PHARM GROUPE (43.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of HANDI-PHARM GROUPE (11.88) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 329.93. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 166.7x. Operating income very largely covers interest expenses: high safety margin.
329.934
166.706
In 2024, the liquidity ratio of HANDI-PHARM GROUPE (329.93) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of HANDI-PHARM GROUPE (166.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 55 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 33 days. The company must finance 22 days of gap between collections and payments. Inventory turnover is 4 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 30 days of revenue, i.e. 398 k€ to permanently finance. Over 2016-2024, WCR increased by +3599%, requiring additional financing.
397 797 €
55 j
33 j
4 j
30 j
Based on 54 transactions of similar company sales
in 2024,
the value of HANDI-PHARM GROUPE is estimated at
1 946 935 €
(range 756 058€ - 3 246 158€).
With an EBITDA of 417 135€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare HANDI-PHARM GROUPE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of HANDI-PHARM GROUPE in 2024 is 4.7 M€.
Yes, HANDI-PHARM GROUPE generated a net profit of 342 k€ in 2024.
The headquarters of HANDI-PHARM GROUPE is located in CHANTONNAY (85110), in the department Vendee.
The tax return of HANDI-PHARM GROUPE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
HANDI-PHARM GROUPE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.